Abstract
Recombinant human proteins play already an important role in therapy, e.g. erythropoietin and colony stimulating factors, while several promising candidates such IL-6, IL-12, thrombopoietin and others are in clinical development. Since the recombinant proteins are copies of endogenous proteins, it was assumed that they would be well tolerated. While this assumption is correct for some, other proteins proved to be a highly toxic. Therefore, preclinical safety assessment of these proteins is necessary. Based on the experience with several proteins, some guidance for the safety assessment can be given. Furthermore, data are presented demonstrating that preclinical toxicity studies have a predictive value for man. Limitations of the classical approach of safety tests and new concepts are discussed.
Keywords
- Cerebral Malaria
- Acute Phase Protein
- Recombinant Human Protein
- Proinflammatory Cytokine Tumor Necrosis Factor
- Strong Cellular Immune Response
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Aggarwal BB, Pocisik E (1992) Cytokines: From clone to clinic. Arch Biochem Biophys 292: 335–359
Aggarwal BB, Puri RK (1995) Human cytokines: Their role in disease and therapy. Blackwell Science Publ. Cambridge
Arai K, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T (1990) Cytokines of immune and inflammatory responses. Annu Rev Biochem 59: 783–836
Beutler B (1992). Tumor necrosis factors: The molecules and their emerging role in medicine. Raven Press, NY.
Brunda MJ (1994) Interleukin-12. Review, J. Leukocyte Biol 55:280–296
Car BD, Eng VM, Schnyder B, Ozmen L, Huang S, Gallay Ph, Heumann D, Aguet M, Ryffel B (1994) INF-g receptor deficient mice are resistant to endotoxic shock. J Exp Med 179: 1437–1444
Car BD, Eng VM, Schnyder B, LeHir M, Shakhov A, Ryffel B (submitted) Role of interferon-g in interleukin 12 induced pathology in mice.
Davies J, Rosenberg M (1994) Mammalian gene studies. Current Opinion Biotechology 5: 604–636
Dexter TM, Garland JM, Test NG (1990) Colony stimulating factors. Marcel Dekker, New York
Eng VM, Car BD, Schnyder B, Lorenz M, Lugli S, Aguet M, Anderson TD, Ryffel B, Quesniaux V (1995) Tlie stimulatory effect of IL-12 on hematopoiesis are inhibited by IL-12 EFNg in vivo. J Exp Med 181: 1893–1898
Gately MK, Warrier RR, Honasoge S, Carvajal DM, Faherty DA, Connaugjiton SE, Anderson TD, Sarmiento U, Hubbard BR, and Murphy M (1993) Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-g in vivo. Int Immunol. 6: 157–167
Gianella-Borradori A (1992) Impact of hemopoietic growth factors in clinical oncology: Present and future. Triangle (Sandoz) 31: 35–43
Grau GE, Lambert PH, Vassalli P, Piguet PF (1993) Tumor necrosis factor/Cachectin as an effector of T cell-dependent immunopathology. In: Experimental Pathology, Vol 34, Cytokine induced Pathology B, Academic Press, Inc., pp. 159–171
Hirano T, Akiro S, Taga T, Kishimoto T (1990) Biological and clinical aspects of interleukin 6. Immunology Today 11: 443–449
Huber B (1994) Gene therapy. Annu NY Acad Sci 716: 1–366
Klug St, Neubert R, Stahlmann R, Thiel R, Ryffel B, Car BD and Neubert D (1994) Effects of recombinant human interleukin 6 (rhlL-6) in marmosets (Callithrix jacchus). Arch Toxicol 68: 619–631
Moore MAS (1991) Hemopoetic growth factors. Annu Rev Immunol 9: 159–191
Robison RL, Myers LA (1993) Preclinical safety assessment of recombinant human GM- CSF in Rhesus Monkeys. In: Experimental Pathology, Vol 34, A, Cytokine-induced Pathology, Academic Press, Inc. pp. 149–172
Ryffel B, Kammüller M, Robison R, Myers L (1992) Pathology induced by interleukin-6 Toxicol Letters 64 /65: 311–319
Ryffel B (1993) Zytokine, Therapeutika, Toxine und Mediatoren der Toxizitat. SWISSMED 15: 16–20
Ryffel B (1994) Pathology induced by cytokines. Int Rev Exp Pathology 34 ( A and B ): A concise review on safety studies on a variety of cytokines, which are contributed by the experts in the specific area
Ryffel B, Car BD, Gunn H, Roman D, Hiestand P, Mihatsch MJ (1994) Interleukin-6 exacerbates glomerulonephritis in (NZBxNZW Fl) mice. Am J Pathol 4, 144: 927–937
Ryffel B, Car BD, Woerly G, Weber M, DiPadova F, Kammuller M, Klug S, Neubert R, Neubert D (1994) Long-term interleukin-6 administration stimulates sustained thrombopoiesis and acute phase protein synthesis in a small primate - the marmoset. Blood 83: 2093–2102
Ryffel B (1995) Interleukin-12: Adjuvans in der Tumortherapy? Therapiewoche Schweiz 11(5)241–244
Ryffel B (1995) Use of knockout mice in pharmacological-toxicological research. Toxicology (1995, in press)
Sarmiento UM, Riley JH, Knaack PA, Lipman JM, Becker JM, Gately K, Chizzonite R, Anderson TD (1994) Biologic effects of recombinant human interleukin-12 in Squirrel Monkeys (Sciureus saimiri). Laboratory Investigation, 71: 862–873
Sundwall A, Ekman L, Johansson HE, Sjöberg B, Sjöholm I (1990) Preclinical evaluation of peptides and recombinant proteins. Skogs Grafiska AB Malmö, Workshop Stockholm Schweden May 7–8 1993
Terrell TG, Green JD (1993) Comparative pathology of recombinant murine interferon-g in mice and recombinant human interferon-g in cynomolgus monkeys. In: Experimental Pathology, Vol 34 B, Cytokine-induced Pathology, Academic Press, Inc. pp 73–101
Trinchieri G, Scott Ph (1994) The role of interleukin 12 in the immunoresponse, disease and therapy. Immunology Today, 15 (10): 460–463
Vassalli P (1992) The pathophysiology of tumor necrosis factor. Annu Rev Immunol 10: 411–452
Woerly G, Ryffel B (1993) The use of receptor assays for the rapid selection of an appropriate animal species for the preclinical investigations of human interleukins. In Vitro Toxicology 6: 67–79
Zabner J, Pertersen DM, Welsh MJ (1994) Safety and efficacy of repetitive adenovirus- mediated transfer of CFTR cDNA to airway epthelia of primates and cotton rats. Nature Genetics 6: 75–81
Zbinden G (1990) Safety evaluation of biotechnology products. Drug Safety 5 (1): 58–64
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Ryffel, B. (1996). Unanticipated Human Toxicology of Recombinant Proteins. In: Seiler, J.P., Kroftová, O., Eybl, V. (eds) Toxicology - From Cells to Man. Archives of Toxicology, vol 18. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61105-6_31
Download citation
DOI: https://doi.org/10.1007/978-3-642-61105-6_31
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64696-6
Online ISBN: 978-3-642-61105-6
eBook Packages: Springer Book Archive